Hua Medicine

12 articles about Hua Medicine

• Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial

  6/18/2020

  Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced topline results from SEED, the first Phase III trial with dorzagliatin.

• Hua Medicine’s Dorzagliatin Demonstrates Improvements in β-Cell Function in Data Presented at the American Diabetes Association’s 80th Scientific Sessions

  6/15/2020

  Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED,.

• Hua Medicine Selected for Inclusion in the MSCI Hong Kong Micro Cap Index

  6/1/2020

  Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, is pleased to announce that the Company has been officially included as a constituent stock of the MSCI Hong Kong Micro Cap Index.

• Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)

  4/27/2020

  HMM0112 is a Phase I trial conducted in the United States in Type 2 Diabetes (T2D) patients with insufficiently controlled blood glucose levels while on metformin, DPP-4 inhibitors or SGLT-2 inhibitors, alone or in combination treatment.

• Hua Medicine Announces 2019 Annual Results

  3/16/2020

  Hua Medicine, a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019.

• Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer

  2/14/2020

  Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development.

• Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

  11/11/2019

  Hua Medicine (Stock Code: 2552.HK) today announced 24-week top-line results from HMM0301 [NCT03173391], the first Phase III trial of a novel first-in-class dual-acting glucokinase (GK) activator, dorzagliatin (HMS5552), which was designed to restore glucose homeostasis in adults with type 2 diabetes.

• Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

  11/8/2019

  Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of type 2 diabetes, today announced that 24-week topline data of dorzagliatin’s monotherapy trial (HMM0301) will be released on November 12, 2019, and management will present the results and answer any questions via conference call.

• Hua Medicine to Raise $200M to Support Novel Diabetes Drug

  1/15/2018

  Hua Medicine of Shanghai expects to spend $200M over the next three years on its novel oral diabetes 2 treatment, dorzagliatin.

• Using Partnerships, Hua Medicine Brings Novel Diabetes Drug To Phase III

  4/13/2017

• Hua Medicine's GKA Diabetes Treatment Passes Proof-of-Concept Trial

  10/17/2016

• Hua Medicine Lands $50 Million In A Series C Funding

  4/21/2016